CA2370237A1 - Methods for the diagnosis and treatment of metastatic prostate tumors - Google Patents

Methods for the diagnosis and treatment of metastatic prostate tumors Download PDF

Info

Publication number
CA2370237A1
CA2370237A1 CA002370237A CA2370237A CA2370237A1 CA 2370237 A1 CA2370237 A1 CA 2370237A1 CA 002370237 A CA002370237 A CA 002370237A CA 2370237 A CA2370237 A CA 2370237A CA 2370237 A1 CA2370237 A1 CA 2370237A1
Authority
CA
Canada
Prior art keywords
flt
prostate
cell
vegf
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002370237A
Other languages
English (en)
French (fr)
Inventor
Sai L. Su
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
ER Squibb and Sons LLC
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2370237A1 publication Critical patent/CA2370237A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/136—Screening for pharmacological compounds
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Pathology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hospice & Palliative Care (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
CA002370237A 1999-04-13 1999-04-13 Methods for the diagnosis and treatment of metastatic prostate tumors Abandoned CA2370237A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US1999/008079 WO2000062063A1 (en) 1999-04-13 1999-04-13 Methods for the diagnosis and treatment of metastatic prostate tumors

Publications (1)

Publication Number Publication Date
CA2370237A1 true CA2370237A1 (en) 2000-10-19

Family

ID=22272560

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002370237A Abandoned CA2370237A1 (en) 1999-04-13 1999-04-13 Methods for the diagnosis and treatment of metastatic prostate tumors

Country Status (6)

Country Link
US (1) US20060234271A1 (enExample)
EP (1) EP1175616A4 (enExample)
JP (1) JP2002540814A (enExample)
AU (1) AU775583B2 (enExample)
CA (1) CA2370237A1 (enExample)
WO (1) WO2000062063A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6136311A (en) 1996-05-06 2000-10-24 Cornell Research Foundation, Inc. Treatment and diagnosis of cancer
US6692965B1 (en) * 1999-11-23 2004-02-17 Chromocell Corporation Isolation of living cells and preparation of cell lines based on detection and quantification of preselected cellular ribonucleic acid sequences
US7611711B2 (en) * 2001-01-17 2009-11-03 Vegenics Limited VEGFR-3 inhibitor materials and methods
WO2003012105A2 (en) * 2001-08-01 2003-02-13 University Of Bristol Vegf isoform
WO2003034903A2 (en) 2001-10-23 2003-05-01 Psma Development Company, L.L.C. Psma antibodies and protein multimers
US20050215472A1 (en) 2001-10-23 2005-09-29 Psma Development Company, Llc PSMA formulations and uses thereof
KR20060129469A (ko) 2004-02-18 2006-12-15 크로모셀 코포레이션 신호 프로브를 이용하는 방법 및 물질
US7414254B2 (en) * 2005-06-28 2008-08-19 United Pharmacy Partners, Inc. Tungsten pig for radio-pharmaceuticals
WO2007015935A2 (en) * 2005-07-29 2007-02-08 Bayer Healthcare Llc Diagnostic methods for the prediction of therapeutic success, recurrence free and overall survival in cancer therapy
ATE509033T1 (de) 2006-03-20 2011-05-15 Univ California Manipulierte anti-prostatastammzellenantigen (psca)-antikörper für krebs-targeting
SG139563A1 (en) * 2006-07-13 2008-02-29 Shimadzu Corp Diagnostic biomolecules
EP2079484A4 (en) * 2006-09-07 2010-03-17 Stemline Therapeutics Inc MONITORING OF CANCER STEM CELLS
JP6126773B2 (ja) 2007-09-04 2017-05-10 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 癌のターゲッティングおよび検出のための高親和性抗前立腺幹細胞抗原（ｐｓｃａ）抗体
US20110189093A1 (en) * 2008-04-14 2011-08-04 Proscan Rx Pharma Prostate specific membrane antigen antibodies and antigen binding fragments
PT2326350E (pt) 2008-09-08 2013-12-10 Psma Dev Company L L C Compostos para matar células cancerosas resistentes a taxano, que expressam psma
ES2712732T3 (es) 2009-02-17 2019-05-14 Cornell Res Foundation Inc Métodos y kits para el diagnóstico de cáncer y la predicción de valor terapéutico
AU2010325969B2 (en) 2009-12-02 2016-10-20 Imaginab, Inc. J591 minibodies and cys-diabodies for targeting human prostate specific membrane antigen
WO2014053564A1 (en) * 2012-10-02 2014-04-10 Metanomics Health Gmbh Means and methods for diagnosing recurrence of prostate cancer after prostatectomy
CN115960230A (zh) 2015-08-07 2023-04-14 伊麦吉纳博公司 靶向分子的抗原结合构建体
WO2018147960A1 (en) 2017-02-08 2018-08-16 Imaginab, Inc. Extension sequences for diabodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635177A (en) * 1992-01-22 1997-06-03 Genentech, Inc. Protein tyrosine kinase agonist antibodies
US5776755A (en) * 1992-10-09 1998-07-07 Helsinki University Licensing, Ltd. FLT4, a receptor tyrosine kinase
US6824777B1 (en) * 1992-10-09 2004-11-30 Licentia Ltd. Flt4 (VEGFR-3) as a target for tumor imaging and anti-tumor therapy
ES2263152T3 (es) * 1994-06-09 2006-12-01 Licentia Oy Anticuerpo monoclonal contra el receptor flt4 tirosina quinasa y su uso en diagnostico y terapia.

Also Published As

Publication number Publication date
EP1175616A1 (en) 2002-01-30
AU775583B2 (en) 2004-08-05
WO2000062063A1 (en) 2000-10-19
JP2002540814A (ja) 2002-12-03
US20060234271A1 (en) 2006-10-19
AU3641099A (en) 2000-11-14
EP1175616A4 (en) 2003-08-13

Similar Documents

Publication Publication Date Title
AU775583B2 (en) Methods for the diagnosis and treatment of metastatic prostate tumors
Qasimi et al. Divergent mechanisms utilized by SOCS3 to mediate interleukin-10 inhibition of tumor necrosis factor α and nitric oxide production by macrophages
DK2081586T3 (en) RSPONDINES AS MODULATORS OF ANGIOGENESE AND VASCULOGENESES
JP2005536186A (ja) リンパ管および血管内皮細胞遺伝子
JP2005520834A (ja) 小細胞肺癌の同定、診断、および治療のための方法および組成物
KR100553300B1 (ko) 혈관신생 및 심혈관형성의 촉진 또는 억제 방법
US20180074062A1 (en) Compositions and methods for the identification, assessment, prevention and therapy of cancer
JP2003531811A5 (enExample)
MXPA05003440A (es) Uso de antigenos a33 y jam-it.
WO2002024957A1 (en) Methods and compositions for modulating angiogenesis
US7348418B2 (en) Carcinoma-related genes and polypeptides and methods of use thereof
JP2006500074A (ja) ポリペプチドおよびこれらをコード化する核酸ならびに肝臓障害および上皮癌の防止、診断、または処置のためのその使用
JP2002526099A (ja) Ｎｌｋ１−相互作用タンパク質
JP2001523455A (ja) Ｃｄｋ２タンパク質およびｃｄｋ２タンパク質複合体
EP1263939B1 (en) 18477, a human protein kinase and uses therefor
EP1553414A1 (en) Methods for the diagnosis and treatment of metastatic prostate tumors
JP2008536869A (ja) Ｋｒｃ活性を調節することによる骨形成および石灰化の調節方法
KR20210046027A (ko) 자가면역질환 및 IL-17A 관련 질환에 대한 바이오마커 및 치료 표적으로서의 AhR-ROR-γt 복합체
HK1080546A (en) Methods for the diagnosis and treatment of metastatic prostate tumors
US7214374B2 (en) 12832, a novel human kinase-like molecule and uses thereof
Mukherjee et al. and Martin T. Zanni
JP2003527831A (ja) エンドゼピン様ポリペプチドおよびエンドゼピン様ポリペプチドをコードするポリヌクレオチド
JP2004528822A (ja) 筋特異的筋節カルシニューリン結合タンパク質（カルサルシン）に関する方法および組成物
BRPI0616656A2 (pt) ativador de membrana conservada de calcineurina (cmac), uma proteìna terapêutica e alvo
JPWO2008111634A1 (ja) 脳・神経に特異的あるいは神経分化に特異的なバイオマーカー

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued